{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:40Z","timestamp":1789972120344,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","jada.ada.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of the American Dental Association"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.adaj.2016.02.011","type":"journal-article","created":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T08:00:36Z","timestamp":1459584036000},"page":"551-560.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Assessing the utility of serum C-telopeptide cross-link of type 1 collagen as a predictor of bisphosphonate-related osteonecrosis of the jaw"],"prefix":"10.1016","volume":"147","author":[{"given":"Reyes","family":"Enciso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Keaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Ahmadieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn T.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parish P.","family":"Sedghizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.adaj.2016.02.011_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.10-1-52","article-title":"Recommendations for zoledronic acid treatment of patients with bone metastases","volume":"10","author":"Berenson","year":"2005","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.adaj.2016.02.011_bib2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","article-title":"Risks and benefits of bisphosphonates","volume":"98","author":"Coleman","year":"2008","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.adaj.2016.02.011_bib3","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"10","key":"10.1016\/j.adaj.2016.02.011_bib4","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"2","key":"10.1016\/j.adaj.2016.02.011_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-011-1429-y","article-title":"Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a\u00a0randomised phase III trial (AZURE: BIG 01-04) for women with stage II\/III breast cancer","volume":"127","author":"Coleman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.adaj.2016.02.011_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"3","key":"10.1016\/j.adaj.2016.02.011_bib7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12663-014-0707-8","article-title":"Bisphosphonate-related osteonecrosis of the jaws and its array of manifestations","volume":"14","author":"Rabelo","year":"2015","journal-title":"J\u00a0Maxillofac Oral Surg"},{"issue":"3","key":"10.1016\/j.adaj.2016.02.011_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","year":"2007","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"5 suppl","key":"10.1016\/j.adaj.2016.02.011_bib9","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"4","key":"10.1016\/j.adaj.2016.02.011_bib10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1359\/jbmr.090203","article-title":"Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw","volume":"24","author":"Baim","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.adaj.2016.02.011_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.joms.2014.10.035","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update and CTX","volume":"73","author":"Schwartz","year":"2015","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"4","key":"10.1016\/j.adaj.2016.02.011_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.tripleo.2010.04.023","article-title":"Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers","volume":"110","author":"Fleisher","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"4","key":"10.1016\/j.adaj.2016.02.011_bib13","first-page":"260","article-title":"Evolution and etiopathogenesis of bisphosphonates induced osteonecrosis of the jaw","volume":"5","author":"Kumar","year":"2013","journal-title":"N\u00a0Am J Med Sci"},{"issue":"12","key":"10.1016\/j.adaj.2016.02.011_bib14","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing,\u00a0prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"suppl 6","key":"10.1016\/j.adaj.2016.02.011_bib15","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s001980070004","article-title":"Preanalytical variability of biochemical markers of bone turnover","volume":"11","author":"Hannon","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.adaj.2016.02.011_bib16","unstructured":"Cochrane Bias Methods Group. Tool to assess risk of bias in cohort studies. The Cochrane Collaboration. Available at: https:\/\/bmg.cochrane.org\/sites\/bmg.cochrane.org\/files\/uploads\/Tool%20to%20Assess%20Risk%20of%20Bias%20in%20Cohort%20Studies.pdf. Accessed March 2,\u00a02016."},{"key":"10.1016\/j.adaj.2016.02.011_bib17","unstructured":"Critical Appraisal Skills Programme (CASP). Critical Appraisal Skills Programme (CASP) case control study checklist 31.05.13. 2013. Available at: http:\/\/media.wix.com\/ugd\/dded87_63fb65dd4e0548e2bfd0a982295f839e.pdf. Accessed March 2,\u00a02016."},{"issue":"2","key":"10.1016\/j.adaj.2016.02.011_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/0019-5413.77126","article-title":"Three-minute critical appraisal of a case series article","volume":"45","author":"Chan","year":"2011","journal-title":"Indian J Orthop"},{"issue":"8","key":"10.1016\/j.adaj.2016.02.011_bib19","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.joms.2014.02.036","article-title":"A\u00a0C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study","volume":"72","author":"Hutcheson","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.adaj.2016.02.011_bib20","unstructured":"Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0, updated March 2011. The Cochrane Collaboration. Available at: http:\/\/handbook.cochrane.org\/. Accessed March 2,\u00a02016."},{"issue":"9","key":"10.1016\/j.adaj.2016.02.011_bib21","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.joms.2010.05.043","article-title":"Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates","volume":"68","author":"Lazarovici","year":"2010","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"6","key":"10.1016\/j.adaj.2016.02.011_bib22","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","article-title":"Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws","volume":"67","author":"Kunchur","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.adaj.2016.02.011_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"issue":"11","key":"10.1016\/j.adaj.2016.02.011_bib24","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.adaj.2016.02.011_bib25","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.adaj.2016.02.011_bib26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bone.2013.08.005","article-title":"Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates","volume":"57","author":"Kim","year":"2013","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.adaj.2016.02.011_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ajoms.2012.06.007","article-title":"Bone turnover and inflammatory markers of bisphosphonate-related osteonecrosis of the jaw in female osteoporosis patients","volume":"25","author":"Choi","year":"2013","journal-title":"J\u00a0Oral Maxillofac Surg Med Pathol"},{"issue":"11","key":"10.1016\/j.adaj.2016.02.011_bib28","first-page":"819","article-title":"Evaluation of serum biomarkers IL-17 and CTX for BRONJ: a pilot clinical case-control study","volume":"41","author":"Lee","year":"2013","journal-title":"J\u00a0Calif Dent Assoc"},{"issue":"11","key":"10.1016\/j.adaj.2016.02.011_bib29","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.oraloncology.2008.01.012","article-title":"Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates","volume":"44","author":"Bagan","year":"2008","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.adaj.2016.02.011_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-0501.2010.01965.x","article-title":"Retrospective study\u00a0of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?","volume":"22","author":"Kwon","year":"2011","journal-title":"Clin Oral Implants Res"},{"issue":"2","key":"10.1016\/j.adaj.2016.02.011_bib31","first-page":"77","article-title":"Bisphosphonate-related osteonecrosis of the jaws: analysis of a case series at a dental school","volume":"34","author":"Scalli","year":"2013","journal-title":"Spec Care Dentist"},{"issue":"11","key":"10.1016\/j.adaj.2016.02.011_bib32","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s00198-011-1882-9","article-title":"Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws","volume":"23","author":"Kwon","year":"2012","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.1016\/j.adaj.2016.02.011_bib33","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/hed.23235","article-title":"Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year cohort study","volume":"35","author":"Lee","year":"2013","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.adaj.2016.02.011_bib34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5125\/jkaoms.2012.38.3.152","article-title":"Clinical investigation of bisphosphonate-related osteonecrosis of the jaws in patients with malignant tumors","volume":"38","author":"Kim","year":"2012","journal-title":"J\u00a0Korean Assoc Oral Maxillofac Surg"},{"issue":"6","key":"10.1016\/j.adaj.2016.02.011_bib35","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10103-011-0974-2","article-title":"Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery?","volume":"26","author":"Atalay","year":"2011","journal-title":"Lasers Med Sci"},{"issue":"12","key":"10.1016\/j.adaj.2016.02.011_bib36","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.joms.2009.04.067","article-title":"Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Kwon","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"4","key":"10.1016\/j.adaj.2016.02.011_bib37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00774-010-0162-7","volume":"28","author":"Yoneda","year":"2010","journal-title":"J\u00a0Bone Miner Metab"},{"issue":"6","key":"10.1016\/j.adaj.2016.02.011_bib38","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.adaj.2016.02.011_bib39","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.adaj.2016.02.011_bib40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1563\/AAID-JOI-D-11-00234","article-title":"Osseointegration of dental implants and osteonecrosis of the jaw in patients treated with bisphosphonate therapy: a systematic review","volume":"39","author":"Chadha","year":"2013","journal-title":"J\u00a0Oral Implantol"},{"issue":"3","key":"10.1016\/j.adaj.2016.02.011_bib41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"2 suppl","key":"10.1016\/j.adaj.2016.02.011_bib42","first-page":"32","article-title":"Multiple systemic diseases complicated by bisphosphonate osteonecrosis: a case report","volume":"3","author":"Carini","year":"2012","journal-title":"Ann Stomatol (Roma)"},{"issue":"9","key":"10.1016\/j.adaj.2016.02.011_bib43","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.joms.2015.03.015","article-title":"High C-terminal cross-linking telopeptide levels are associated with a minimal risk of osteonecrosis of the jaws in patients taking oral bisphosphonates and having exodontia","volume":"73","author":"Friedlander","year":"2015","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"2","key":"10.1016\/j.adaj.2016.02.011_bib44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11845-011-0790-5","article-title":"A\u00a0role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery?","volume":"181","author":"O\u2019Connell","year":"2012","journal-title":"Ir J Med Sci"},{"issue":"1","key":"10.1016\/j.adaj.2016.02.011_bib45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.adaj.2016.02.011_bib46","first-page":"1243","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association council on scientific affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"JADA"},{"issue":"2","key":"10.1016\/j.adaj.2016.02.011_bib47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.oooo.2012.08.455","article-title":"Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw","volume":"115","author":"Sedghizadeh","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"}],"container-title":["The Journal of the American Dental Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817716000994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817716000994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T15:52:16Z","timestamp":1536853936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002817716000994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0002817716000994"],"URL":"https:\/\/doi.org\/10.1016\/j.adaj.2016.02.011","relation":{},"ISSN":["0002-8177"],"issn-type":[{"value":"0002-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the utility of serum C-telopeptide cross-link of type 1 collagen as a predictor of bisphosphonate-related osteonecrosis of the jaw","name":"articletitle","label":"Article Title"},{"value":"The Journal of the American Dental Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adaj.2016.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Dental Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}